Skip to content

Autologous Fat Grafting in Radiated Soft Tissue Reconstruction

A Pilot Study Treating Radiation Injury With Autologous Fat Transfer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05890196
Enrollment
10
Registered
2023-06-06
Start date
2023-03-01
Completion date
2025-12-31
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Fat Grafting, Radiation Fibrosis

Brief summary

The purpose of this study is to observe the effect of autologous fat grafting on soft tissue reconstruction of the breast following radiation treatment. Moving fat from one part of the body to another has been used for reconstruction for hundreds of years. However, it is not fully understood how well this works in reconstruction after radiation is used for cancer treatment.

Detailed description

This is a single-arm, prospective pilot study that will objectively assess outcomes in patients electively undergoing AFT for breast or chest wall reconstruction. Patients planning to undergo autologous fat transfer for breast or chest wall reconstruction will be enrolled prospectively. As this is a pilot study, the study team plans to enroll ten (10) patients to demonstrate the feasibility of the protocol and pathway as well as establish preliminary data for extramural funding. The research will include capturing 2-dimensional (2-D) and 3-dimensional (3-D) photographs as well as ultrasound (US) soft tissue assessments to determine volume retention and changes in the reconstructed area. Participants will undergo this imaging of their breast and chest wall and complete two questionnaires to evaluate patient satisfaction, quality of life, and late effects of radiation following fat grafting over a 12-month period, all standard of care. The 3D photographs and US are routinely used in practice but will be performed for research purposes in this study.

Interventions

None listed

Sponsors

University of Chicago
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able to give consent * Undergoing elective autologous fat grafting * Previously treated for breast cancer * Previous treatment included radiation therapy to the breast/chest wall.

Exclusion criteria

* Unable to give consent * No history of radiation to the breast or chest wall * No prior treatment for breast cancer * No indication for autologous fat grafting * Currently pregnant or breastfeeding * Currently consuming nicotine products (smoking, vaping, patches, gum) * Under the age of 18

Design outcomes

Primary

MeasureTime frameDescription
Change in Skin Fibrometry before and after fat transfer in reconstruction.12 monthsSoft tissue assessment is made using a non-invasive device SkinFibrometer (Delfin Kuopio, Finland) that measures tissue edema and skin elasticity. Measurements will be taken in all four quadrants of the affected (radiated) breast or reconstructed breast before and after the grafting procedure.

Secondary

MeasureTime frameDescription
Change in Radiation Injury before and after fat transfer.12 monthsRadiation injury assessment is made using the validated tool Late Effects Normal Tissue Task Force - Subjective Objective Management and Analytic (LENT-SOMA) score. Assessment will be made before and after the fat transfer procedure. Overall, scores are based on 12 categories, scored 0-4 with a higher score indicating more significant radiation injury.
Change in patient reported satisfaction of the breast measure before and after fat transfer.12 monthsThe BREAST Q validated patient survey measures several realms related to breast reconstruction and allows an assessment of satisfaction and physical well-being before and after reconstruction. The survery responses are tallied and converted to a score of 100 with a higher score being more satisfied or better outcome. In addition, a change in score of 8 or more points is a clinically meaningful difference according to normative studies.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026